Congenital Heart Disease, Pulmonary Valve Disorder
Conditions
Brief summary
In this trial we intend to evaluate the safety and effectiveness of the INSPIRIS valve prothesis in the pulmonary position in patients of five years or older, with congenital or acquired pulmonary valve disease, requiring replacement of their native or prosthetic pulmonary valve.
Detailed description
Up to 40 subjects will be invited to participate in this trial after the indication for pulmonary valve replacement has been established. At the inclusion visit, patients will be screened according to the inclusion / exclusion criteria. After written informed consent, a detailed history will be obtained, and the study related exams will be performed. The procedure will be performed through a median sternotomy with the help of cardiopulmonary bypass in a beating or arrested heart fashion depending on the individual surgeon's discretion. Any additional or residual defects will concomitantly be addressed. Either a native or prosthetic pulmonary valve will be replaced by an Edwards Inspiris valve (Edwards Lifesciences, Unterschleissheim, Germany). If a conduit is required, the valve will be sewn into a suitable prosthesis beforehand. Subjects will be seen regularly after pulmonary valve implantation at hospital discharge, 6-month, 1 year and 2 years after surgery. A cardiac magnetic resonance imaging will be performed at inclusion and 2 years after surgery. Total enrollment period for the study is estimated to be two years. The trial starts with the enrollment of the first patients and ends after the last patient enrolled has completed the two-year visit or has exited the study.
Interventions
PROCEDUREPulmonary valve replacement
Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.
Sponsors
Medical University of Vienna
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
5 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. pulmonary valve disease requiring pulmonary valve replacement of their native or prosthetic valve, equal to or greater than five years of age. 2. Patients and/or patient´s legal representatives must provide written informed consent as approved and required by the respective institutional review board and agree to its provisions. 3. The patient has completed all preoperative investigations.
Exclusion criteria
1. Requires emergency surgery 2. Has acute myocardial infarction (MI) within 30 days prior to screening date 3. Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient ischemic attack (TIA) within six months prior to screening date 4. Has hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to screening date 5. Has active endocarditis/myocarditis or endocarditis/myocarditis within three months prior to screening date 6. Has renal insufficiency as determined by creatinine level ≥ 2.5 mg/dL within 60 days prior to screening visit or end-stage renal disease 7. Has documented: 1. leukopenia (WBC \< 3.5x 103/µL), 2. acute anemia (Hgb\<10.0 g/dL or 6 mmol/L), or 3. thrombocytopenia (platelet count \< 50x 103/µL) accompanied by history of bleeding diathesis or coagulopathy within 60 days prior screening date 9\. Diagnosed with abnormal calcium metabolism and/or hyperparathyroidism 10. Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation 11. RVOT aneurysm unless treated during pulmonary valve replacement surgery 12. Has prior organ transplant or is currently an organ transplant candidate 13. Was previously implanted with study trial device 14. Previously implanted with an aortic, mitral, or tricuspid bioprosthetic valve or mechanical valve 16. Has presence of non-cardiac disease limiting life expectancy to less than 12 months 17. Is currently or has recently participated (within six weeks) in another investigational drug or device trial 18. Positive urine or serum pregnancy test in female subjects of child-bearing potential and/or nursing mothers 20. Currently incarcerated or unable to give voluntary informed consent 21. Documented history of substance (drug or alcohol) abuse within the last five years prior to screening date
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from death and reoperation | 2 years after implantation | The primary safety endpoint for the trial is freedom from device or procedure related death and/or reoperation at 2 years after implantation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety endpoints | 2 years after implantation | all-cause mortality, structural valve deterioration, paravalvular leak, non-structural valve deterioration, transvalvular leak, trial valve-related mortality, endocarditis, valve thrombosis, explant and thromboembolism |
Countries
Austria
Contacts
Primary ContactDaniel Zimpfer, Prof. PD. Dr.
Outcome results
None listed